CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non–Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy
Overview of attention for article published in Journal of Clinical Oncology, March 2024
Altmetric Badge
About this Attention Score
-
In the top 5% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (97th percentile)
-
High Attention Score compared to outputs of the same age and source (86th percentile)
Readers on
- mendeley
- 52 Mendeley